Completed OBSERVATIONAL NCT04873141

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia: Experience From Single Center of Pakistan

Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University

Conditions Covid-19 Pneumonia Cytokine Release Syndrome

Interventions Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)

Updated 3 times since 2021 Last updated: May 4, 2021 Started: Apr 28, 2020 Primary completion: Jun 22, 2020 Completion: Jun 22, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Covid-19 Pneumonia and Cytokine Release Syndrome, this trial is completed. The trial is conducted by Shaheed Zulfiqar Ali Bhutto Medical University and has accumulated 3 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jun 2021 — Jul 2024 [monthly]

Completed

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shaheed Zulfiqar Ali Bhutto Medical University

Data source: Shaheed Zulfiqar Ali Bhutto Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Islamabad, Pakistan